Elicera Therapeutics AB (FRA:8E8) WACC %:-4.44% (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8E8 Elicera Therapeutics AB FRA:8E8
40 GF Score
Price €0.21
! 1 Warning Sign
View Full Analysis

What is Elicera Therapeutics AB WACC %?

Elicera Therapeutics AB FRA:8E8 -3.87% 40 WACC % is -4.44% as of Jul. 16, 2026. GuruFocus rates FRA:8E8 with a GF Score™ of 40/100. The stock has 1 warning sign investors should review. Among 1,421 Biotechnology companies, Elicera Therapeutics AB ranks better than 95.21% on this metric.

As of today (2026-07-16), Elicera Therapeutics AB's weighted average cost of capital is -4.44%%. Elicera Therapeutics AB's ROIC % is -288.17% (calculated using TTM income statement data). Elicera Therapeutics AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.

For a comprehensive WACC calculation, please access the WACC Calculator.


Elicera Therapeutics AB  (FRA:8E8) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Elicera Therapeutics AB's weighted average cost of capital is -4.44%%. Elicera Therapeutics AB's ROIC % is -288.17% (calculated using TTM income statement data). Elicera Therapeutics AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

Elicera Therapeutics AB WACC % Historical Data

* Premium members only.

The historical data trend for Elicera Therapeutics AB's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elicera Therapeutics AB WACC % Chart

Elicera Therapeutics AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
WACC %
Get a 7-Day Free Trial 6.14 7.97 8.21 -2.46 -0.72

Elicera Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.52 -0.57 0.52 -0.72 2.82

FRA:8E8 vs VRTX, REGN, ALNY: WACC % Comparison

For the Biotechnology subindustry, Elicera Therapeutics AB's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elicera Therapeutics AB WACC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicera Therapeutics AB's WACC % distribution charts can be found below:

* The bar in red indicates where Elicera Therapeutics AB's WACC % falls into.


FRA:8E8
40GF Score
Elicera Therapeutics AB FRA:8E8
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elicera Therapeutics AB WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Elicera Therapeutics AB's market capitalization (E) is €15.751 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Mar. 2026, Elicera Therapeutics AB's latest one-year quarterly average Book Value of Debt (D) is €0 Mil.
a) weight of equity = E / (E + D) = 15.751 / (15.751 + 0) = 1
b) weight of debt = D / (E + D) = 0 / (15.751 + 0) = 0

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 2.7446%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Elicera Therapeutics AB's beta is -1.1978.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 2.7446% + -1.1978 * 6% = -4.4422%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Mar. 2026, Elicera Therapeutics AB's interest expense (positive number) was €0.002 Mil. Its total Book Value of Debt (D) is €0 Mil.
Cost of Debt = 0.002 / 0 = %.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0 / -1.33 = 0%.

Elicera Therapeutics AB's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=1*-4.4422%+0*%*(1 - 0%)
=-4.44%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of -4.44% mean?
Elicera Therapeutics AB (FRA:8E8) has a WACC % of -4.44% as of Jul. 16, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Elicera Therapeutics AB and its competitors. According to the industry distribution chart, Elicera Therapeutics AB ranks #68 out of 1421 companies in the Biotechnology industry, placing it in the top 4.8%.
Is Elicera Therapeutics AB's WACC % too high?
Elicera Therapeutics AB's current WACC % is -4.44%. Based on the distribution chart, Elicera Therapeutics AB ranks #68 out of 1421 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Elicera Therapeutics AB has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Elicera Therapeutics AB's WACC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Elicera Therapeutics AB ranks #68 out of 1421 companies for WACC %. This places Elicera Therapeutics AB in the top 5% of its industry — outperforming the majority of peers. The industry median WACC % is 10.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Biotechnology company?
The median WACC % among Biotechnology companies is 10.00, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Elicera Therapeutics AB and its competitors. For the Biotechnology industry, the median WACC % is 10.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elicera Therapeutics AB's current WACC % is -4.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicera Therapeutics AB stock overvalued right now?
Elicera Therapeutics AB (FRA:8E8) has a current WACC % of -4.44%. The current WACC % is -4.44%. Elicera Therapeutics AB's overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Elicera Therapeutics AB (FRA:8E8), the current WACC % is -4.44% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elicera Therapeutics AB Business Description

Other Exchanges ELIC:Sweden
Address Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, 412 51
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. Its product portfolio consists of four drug candidates, including two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to the universal CAR T-cell technology platform, iTANK (ELC-001). The Company is running four internal immunotherapy development projects, comprising two CAR T-cell programs and two oncolytic virus programs.
40GF Score

Get the complete analysis for FRA:8E8

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.21
Price